By Ibrahim Hamdi Hacicaferoglu
ISTANBUL (AA) - US oncologists demanded accountability of artificial intelligence (AI) developers over potential medical application errors in cancer treatment, according to a recent article in the Journal of the American Medical Association (JAMA).
In a study published in JAMA, US oncologists highlighted concerns regarding the use of artificial intelligence (AI) in cancer treatment and urged accountability of AI developers for potential medical application errors.
The study surveyed 204 oncology experts practicing in the US between November 2022 and July 2023.
Approximately 90% of the respondents advocated for AI developers to assume responsibility for potential legal issues arising from the use of AI in cancer treatment.
Regarding the allocation of responsibility, 47.1% of oncologists suggested that responsibility should lie with doctors, while 43.1% believed it should be shared by hospitals.
Furthermore, 81.4% of oncologists emphasized the necessity of obtaining patients' consent for treatments involving AI.
Regarding decision-making conflicts between AI recommendations and doctors' expertise, 36.8% of American physicians suggested that patients should have the final say.
As the US Food and Drug Administration (FDA) approves AI models for use in oncology, researchers point to the potential for AI to play a revolutionary role in this field.
However, the survey highlights the need for clear guidelines on responsibility and accountability in AI-assisted cancer treatment.